Neuberger Berman Group LLC Has $275.06 Million Stake in AbbVie Inc. $ABBV

Neuberger Berman Group LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 4.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,187,956 shares of the company’s stock after selling 52,298 shares during the quarter. Neuberger Berman Group LLC owned approximately 0.07% of AbbVie worth $275,059,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after buying an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. increased its position in AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares in the last quarter. Andra AP fonden increased its position in AbbVie by 3.3% in the 2nd quarter. Andra AP fonden now owns 74,800 shares of the company’s stock valued at $13,884,000 after acquiring an additional 2,400 shares in the last quarter. Finally, Golden State Wealth Management LLC raised its stake in shares of AbbVie by 23.7% in the second quarter. Golden State Wealth Management LLC now owns 2,627 shares of the company’s stock worth $488,000 after acquiring an additional 503 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY/Q1 outlook — AbbVie posted better‑than‑expected Q4 EPS and revenue and gave FY‑2026 guidance (14.37–14.57 EPS), supporting the bull case for continued top‑line and EPS growth. AbbVie (ABBV): Buy, sell, or hold post Q4 earnings?
• Positive Sentiment: Pipeline catalysts: neuroscience momentum and new approvals could drive revenue — the neuroscience unit generated ~$10.8B in 2025 and analysts see upside to ~$12.5B in 2026 as Vyalev ramps and tavapadon awaits FDA review. Will AbbVie’s Neuroscience Segment Continue to Aid Top Line in 2026?
• Positive Sentiment: Positive Phase‑3 SKYRIZI Crohn’s data strengthens the immunology franchise and expands commercial potential for risankizumab. This data is a material upside to long‑term revenue expectations for immunology products. Did Positive Phase 3 SKYRIZI Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?
• Neutral Sentiment: Analyst/market attention: some bullish writeups call ABBV a core, buy‑and‑hold dividend name and note the stock has rallied since earnings — supportive for sentiment but already reflected in recent gains. AbbVie: The only big pharma stock I’d consider a buy-and-never-sell
• Neutral Sentiment: Operational investment: AbbVie will spend $380M to expand its North Chicago campus — a long‑term capacity/R&D bet that supports future growth but increases near‑term capex. AbbVie to invest $380 million in North Chicago campus to make next generation medicines
• Negative Sentiment: Debt issuance: AbbVie completed an $8B senior notes offering, which increases leverage and raises capital‑structure risk that investors may price in, especially given the company’s already elevated payout metrics. AbbVie Completes $8 Billion Senior Notes Financing Offering
• Negative Sentiment: Dividend and leverage concerns: analysts caution that a very high payout ratio and significant debt levels warrant caution for income investors despite strong free cash flow. That raises risk of multiple compression if growth slows. Dividend Stock Analysis – Abbvie Inc.
• Negative Sentiment: Near‑term price pressure: recent sessions show ABBV underperforming the wider market on profit‑taking and macro moves, which can amplify volatility after the post‑earnings run. AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ABBV. Evercore reduced their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. BMO Capital Markets restated an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research report on Thursday, January 15th. UBS Group reduced their price objective on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Barclays assumed coverage on AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective on the stock. Finally, Royal Bank Of Canada initiated coverage on AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Trading Down 0.8%

Shares of AbbVie stock opened at $230.41 on Friday. The stock’s fifty day simple moving average is $224.72 and its 200 day simple moving average is $223.97. The company has a market capitalization of $407.40 billion, a PE ratio of 97.63, a PEG ratio of 0.81 and a beta of 0.34. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Insider Activity at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.25% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.